INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 179 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2016. The put-call ratio across all filers is 0.73 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $7,264,000 | +83.5% | 60,000 | +71.4% | 0.10% | +66.1% |
| Q1 2017 | $3,959,000 | +8.8% | 35,000 | +4.5% | 0.06% | +1.7% |
| Q4 2016 | $3,640,000 | -3.9% | 33,500 | +45.7% | 0.06% | -10.8% |
| Q3 2016 | $3,786,000 | +21.3% | 23,000 | +5.2% | 0.06% | +10.2% |
| Q2 2016 | $3,120,000 | +50.1% | 21,869 | +57.1% | 0.06% | +55.3% |
| Q4 2015 | $2,079,000 | -6.9% | 13,921 | +3.4% | 0.04% | -15.6% |
| Q3 2015 | $2,232,000 | -5.9% | 13,459 | +36.9% | 0.04% | -2.2% |
| Q2 2015 | $2,372,000 | -10.3% | 9,828 | +4.8% | 0.05% | -8.0% |
| Q1 2015 | $2,644,000 | +127.7% | 9,375 | +26.0% | 0.05% | +117.4% |
| Q4 2014 | $1,161,000 | +196.2% | 7,442 | +349.7% | 0.02% | +187.5% |
| Q3 2014 | $392,000 | -97.9% | 1,655 | -99.4% | 0.01% | -98.2% |
| Q4 2013 | $18,278,000 | -85.3% | 267,692 | +48.7% | 0.44% | -86.9% |
| Q3 2013 | $124,252,000 | +802.6% | 180,000 | -41.4% | 3.32% | +592.7% |
| Q2 2013 | $13,766,000 | – | 307,070 | – | 0.48% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |